Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features

Figures & data

Table 1 Dose of teicoplanin administration to the patients

	Administration example (1st–2nd day: total doses on 2 days) (mg)	Age (years)	Weight (kg)	Albumin (mg/L)	Creatinine (mg/L)
Group 1 (n = 11)	1200–600 (1800) 600–1200 (1800)	42.0 ± 10.8	53.7 ± 5.7	3.4 ± 0.6	0.6 ± 0.2
Group 2 (n = 6)	800–800 (1600)	42.3 ± 24.5	48.8 ± 7.9	2.9 ± 0.8	0.6 ± 0.2
Group 3 (n = 11)	800–400 (1200)	53.5 ± 15.1	49.0 ± 11.0	3.0 ± 0.5	1.1 ± 0.7

Note: Age, weight, albumin, and creatinine were expressed as mean ± standard deviation.

Figure 1 Teicoplanin trough concentrations.

Note: Data are expressed as means ± standard deviation.

Table 2 Treatment success and adverse effects rates in each group

	Group A TEIC: 15–20 mg/L (n = 28)	Group B TEIC:>20 mg/L (n = 27)	Group C VCM: 15–20 mg/L (n = 50)	Group D VCM:>20 mg/L (n = 34)
Treatment response
Success	24/28 (85.7%)	22/27 (81.5%)	46/50 (92.0%)	31/34 (91.2%)
Adverse effects
Nephrotoxicity	2/28 (7.1%)	1/27 (3.7%)	7/50 (14.0%)	4/34 (11.8%)
Hepatotoxicity	4/28 (14.3%)	3/27 (11.1%)	9/50 (18.0%)	7/34 (20.6%)

Abbreviations: TEIC, teicoplanin; VCM, vancomycin.